optic neuritis
Biogen expands portfolio in deal with Alcyone Therapeutics
The agreement gives Biogen full rights to a potential therapy for patients with neurological disorders
Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib
The immune-mediated disease affects more than 2.9 million people worldwide
Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study
Approximately 2.9 million people worldwide are living with the neurodegenerative disease
Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study
The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease
Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review
Approximately 2.9 million people worldwide are living with the neurodegenerative disease
Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use
The neurological disorder affects more than 150,000 people in the UK
UK drug repurposing study identifies several potential dementia treatments
An estimated 982,000 people in the UK are currently living with the neurodegenerative disease
Sanofi’s BTK inhibitor tolebrutinib granted FDA breakthrough designation for MS
The neurological disorder affects approximately 2.9 million people globally
Sanofi shares positive late-stage results for investigational BTK inhibitor in progressive MS
Tolebrutinib is currently being evaluated in various forms of the neurological disorder
Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS
The subcutaneous formulation has the same twice-yearly dosing schedule as the previously approved intravenous infusion
Roche shares positive 48-week results for investigational BTK inhibitor in relapsing MS
Approximately 2.9 million people worldwide are affected by the neurological disease
Sanofi’s investigational BTK inhibitor tolebrutinib shows promise in phase 3 MS study
The neurological disorder affects approximately 2.9 million people worldwide